24.04.2023 - 27.04.2023Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 08:00 - 17:00
Kongressthemen The TCE pipeline is ever-growing and there are multiple different formats, engagers and costimulatory being studied in over 90 trials, with over a hundred projects in the preclinical stage. To treat hematological malignancies, the majority of pharmaceutical and biotech companies are focusing on lymphocyte-restricted tumor-associated antigens such as CD19, CD20, BCMA, CD33, and CD123.